Systemic therapy for advanced hepatocellular carcinoma (HCC) includes multi‐kinase inhibitors with anti‐vascular endothelial growth factor (VEGF) activity and anti‐VEGF monoclonal antibodies in combination with immune checkpoint inhibitors. Here, VEGFA is linked to hepatocellular carcinoma.